Block Listing Review and Total Voting Rights

RNS Number : 8348X

ReNeuron Group plc

01 September 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review

and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

Name:	ReNeuron Group plc
Name of Scheme:	ReNeuron Share Option Schemes
Period of Return:	From 1 March 2022 to 31 August 2022
Balance of unallotted securities under scheme(s) from previous return:	3,455,769 Ordinary Shares (of 1p each)
Plus : The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):	-
Less : Number of securities issued/allotted under scheme(s) during period	82,270
Equals : Balance under scheme(s) not yet issued/allotted at end of period:	3,373,499 Ordinary Shares
Number and class of securities originally admitted and the date of admission:	20,000 ordinary shares on 13 May 2010

Total Voting Rights

At 31 August 2022, the Company had 57,145,893 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 57,145,893 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

ReNeuron	www.reneuron.com/investors
Iain Ross, Chairman	Via Walbrook PR
Catherine Isted, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking)	[phone]
Allenby Capital Limited (Joint Broker)	[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus/Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs. 

ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability. 

The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories. 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit   www.reneuron.com

 

END

 

 

TVRBKDBQABKDBFN